← TG THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($78.3m) | ($118.5m) | ($173.5m) | ($172.9m) | ($279.4m) | ($348.1m) | ($198.3m) | $12.7m | $23.4m | $447.2m | — | |
| Depreciation, Depletion and Amortization | $63k | $82k | $88k | $100k | $158k | $282k | $303k | $211k | $68k | $59k | $305k | |
| Amortization of Debt Issuance Costs | — | $0 | $0 | $772k | $925k | $1.1m | $1.8m | $2.4m | $2.0m | $1.2m | — | |
| Amortization of Intangible Assets | — | — | — | — | — | $212k | $212k | — | — | — | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | $0 | $0 | — | — | — | — | ($348.0m) | ($343.4m) | |
| Share-based Payment Arrangement, Noncash Expense | $7.5m | $15.9m | $12.9m | $7.8m | $80.3m | $61.3m | $19.2m | $37.9m | $42.5m | $64.7m | $81.2m | |
| Share-based Payment Arrangement, Expense | $7.5m | — | $12.9m | $11.3m | — | — | — | $37.9m | $42.5m | $64.7m | $81.2m | |
| Goodwill, Impairment Loss | — | — | — | $0 | $0 | $0 | $0 | — | — | — | — | |
| Nonoperating Income (Expense) | $716k | $236k | $918k | ($3.8m) | ($5.8m) | ($3.3m) | ($5.5m) | ($7.6m) | ($16.3m) | ($15.9m) | — | |
| Other Nonoperating Income (Expense) | — | — | — | — | — | — | — | $5.0m | $7.7m | $10.8m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | — | $0 | $0 | $1.4m | ($1.4m) | $51.1m | $78.1m | $176.4m | ($170.0m) | |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | — | $36.9m | $66.9m | $33.5m | ($70.8m) | |
| Inventory Write-down | — | — | — | — | — | — | — | — | — | $6.2m | — | |
| Net Cash Provided by (Used in) Operating Activities | ($61.6m) |
($93.8m)
-52.24%
|
($128.9m)
-37.50%
|
($132.8m)
-3.01%
|
($214.5m)
-61.52%
|
($295.6m)
-37.82%
|
($176.2m)
+40.41%
|
($31.4m)
+82.17%
|
($40.5m)
-28.98%
|
($24.8m)
+38.86%
|
$17.9m
+172.16%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $344k | $2k | $90k | $131k | $357k | $401k | $14k | $0 | $45k | $214k | ($491k) | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | $140.4m | $605.4m | $350.3m | $174.1m | $217.5m | $311.0m | $199.5m | — | |
| Gain (Loss) on Sale of Investments | ($33k) | $0 | $0 | — | — | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | $26.5m | ($8.2m) | $1.2m | ($718k) | ($24.5m) | ($332k) | ($20.0m) | ($50.7m) | ($1.0m) | $13.8m | $21.9m | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | $0 | $0 | ($4.6m) | $0 | — | |
| Proceeds from Issuance of Common Stock | — | — | $113.7m | — | — | $2.2m | $0 | $46.3m | $0 | $0 | $0 | |
| Net Cash Provided by (Used in) Financing Activities | $5.0m |
$133.7m
+2564.66%
|
$113.6m
-14.98%
|
$204.2m
+79.70%
|
$679.8m
+232.90%
|
$41.4m
-93.91%
|
($391k)
-100.94%
|
$72.7m
+18694.63%
|
$128.5m
+76.78%
|
($89.7m)
-169.81%
|
$313.7m
+449.64%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | $31.7m | ($14.1m) | $70.7m | $440.8m | ($254.5m) | ($196.6m) | ($9.4m) | $87.0m | ($100.7m) | $483.9m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $31.7m | $43.2m | $113.9m | $554.7m | $300.2m | $103.6m | $94.2m | $181.2m | $80.5m | $483.9m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $0 | — | — | — | — | — | — | $1.5m | $914k | $1.5m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | $4.5m | $3.5m | $5.4m | $8.8m | $18.5m | $24.2m | — | |
| Income Taxes Paid, Net | — | — | — | — | — | — | — | — | $500k | $7.9m | — | |
| Additional Financial Items | ||||||||||||
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | — | — | — | — | — | ($754k) | ($298k) | — | |
| General and Administrative Expense | $9.9m | $16.3m | $15.2m | $15.0m | $107.8m | — | — | — | — | — | — | |
| Goodwill | $799k | $799k | $799k | $799k | $799k | $799k | $799k | $799k | — | — | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $390k | $2.2m | ($339.8m) | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $24.0m | $26.7m | — | |
| Operating Expenses | $79.1m | $118.9m | $174.6m | $169.2m | $273.7m | $351.5m | $195.6m | — | — | — | — | |
| Operating Lease, Expense | — | — | — | — | $2.7m | $2.2m | $2.7m | $2.2m | — | — | — | |
| Payments of Financing Costs | $14k | $0 | $0 | $795k | $0 | $1.0m | — | $125k | $889k | $0 | — |